94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
SYSTEMATIC REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1514831
This article is part of the Research Topic Crosstalk between Lung Cancer and Fibrosis: Pathogenesis and Therapeutic Strategies View all 3 articles
Pulmonary Fibrosis Complicated by Lung Cancer: Bibliometric Analysis from 2004 to 2024 -Research Status, Trends and Future Directions
Provisionally accepted- 1 Shandong University of Traditional Chinese Medicine, Jinan, China
- 2 Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China
Objective: Although research on the association between pulmonary fibrosis and lung cancer is of great significance, to date, no bibliometric analysis has been conducted on the comorbidity of these two diseases. This study aims to explore the current status and cutting -edge trends in this field through bibliometric analysis, and to establish new directions for future research.Methods: Using the Web of Science Core Collection database, statistical calculations, graphic, and data visualization tools such as CiteSpace, VOSviewer, and Biblimatrixbiblioshiny were adopted.Results: A total of 2,234 original Articles and Reviews on pulmonary fibrosis complicated by lung cancer published between 2004 and 2024 were identified. A slow growth trend in publications related to pulmonary fibrosis complicated by lung cancer was observed. The United States, Japan, and China were the countries with the greatest contributions. Professor Michael Kreuter from Marienhaus Clinic, Mainz, Germany, and the University of Michigan published the most articles. Through cluster analysis of cocited literature, five main clusters were identified. Keyword analysis predicted that "nintedanib", "pirfenidone", "immunotherapy", etc. might become hot topics in the field of the comorbidity of pulmonary fibrosis and lung cancer.This bibliometric analysis shows that the literature related to the comorbidity of pulmonary fibrosis and lung cancer is on a continuous upward trend.The research hotspots and trends identified in this study provide a reference for indepth research in this field, aiming to promote the development of research on the comorbidity of pulmonary fibrosis and lung cancer.
Keywords: Pulmonary Fibrosis, Nintedanib, lung cancer, Pirfenidone, Immunotherapy, Bibliometrics
Received: 21 Oct 2024; Accepted: 27 Feb 2025.
Copyright: © 2025 Li, Wu, Ma, Yuan, Li, Zhang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Boyang Li, Shandong University of Traditional Chinese Medicine, Jinan, China
Xue Liu, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, Shandong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.